Tumor necrosis factor-inducing activities of Cryptococcus neoformans components

Infection and Immunity

Volumn 64, Issue 12, 1996, Pages 5199-5204

  Delfino, Demetrio ^a   Cianci, Luigi ^a   Migliardo, Maria ^a   Mancuso, Giuseppe ^a   Cusumano, Vitaliano ^a   Corradini, Claudio ^b   Teti, Giuseppe ^a,c  

^a UNIVERSITY OF MESSINA   (Italy)

^b CNR   (Italy)

^c Istiluto di Microhiologia   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; BETA GLUCAN; GLUCURONOXYLOMANNAN; MANNAN; MANNOPROTEIN; POLYSACCHARIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; BLOOD CULTURE; CONTROLLED STUDY; CRYPTOCOCCUS NEOFORMANS; HUMAN; HUMAN CELL; LEUKOCYTE; NONHUMAN; PRIORITY JOURNAL; SALMONELLA ENTERITIDIS;

EID: 0029850702     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/iai.64.12.5199-5204.1996     Document Type: Article

References (42)

1. Aguirre, K., E. A. Havell, G. W. Gibson, and L. L. Johnson. 1995. Role of tumor necrosis factor and gamma interferon in acquired resistance to Cryptococcus imifomans in the central nervous system of mice. Infect. Immun. 63:1725-1731.
2. Bozette, S. A., K. A. Larsen, J. Chiu, et al. 1991. A placebo-controlled trial of maintenance therapy with fluconazole after treatment of cryptococcal meningitis in the acquired immunodeficiency syndrome. N. Engl. J. Med. 324:5811-584.
3. Buchanan, K. L., and J. W. Murphy. 1993. Characterznation of cellular infiltrates and cylokine production during the expression phase of the anticryptococcal delayed-type hypersensitivity response. Infect. Immun. 61:2854-2865.
4. Cameron, M. L., D. L. Granger, J. B. Weinberg, W. J. Kozumbo, and H. S. Koren. 1990. Human alveolar and peritoneal macrophages mediate fungislasis independently of L-arginine oxidation to nitrite or nitrate. Am. Rev. Rcspir. Dis. 142:1313-1319.
5. Casadevall, A., E. D. Spitzer, D. Webb, and M. G. Rinaldi. 1993 Susceptibilities of serial Cryptocorrus neofonnans isolates from patients with recurrent cryptococcal meningitis toamphotericin B und flucomizolc. Antimicrob. Agents Chemother. 37:1383-1386.
6. Cavaillon, J. M., and C. Aznar. 1992. Cytokines et infections fongiques. J. Mycol. Méd. 2:61-67.
7. Chandler, F. W. 1985. Pathology of the mycoses in patients with the acquired immunodeficiency syndrome (AIDS). Curr. Top. Mod. Mycol. 1:1-23.
8. Chen, G. H., J. L. Curtis, C. H. Mody, P. J. Christensen, L. R. Armstrong, and G. B. Toews. 1994. Effect of granulocyle-macrophage colony-stimulating factor on rat alveolar macrophage anticryptococcal activity in vitro. J. Immunol. 152:724-734.
9. Cherniuk, R., L. C. Morris, B. C. Anderson, and S. A. Meyer. 1991. Facilitated isolation, purification, and analysis of glucuronoxylomannan of Ciyptococcus neofonnam. Infect. Immun. 59:59-64.
10. Chuck, S. L., and M. A. Sande. 1989. Infections with Cryptococcus neoformans in the acquired immunodeficiency syndrome. N. Engl. J. Mod. 321:794-799.
11. Collins, H. L., and G. J. Bancroft. 1942. Cytokine enhancement of complement-dependent phagocytosis by macrophages: synergy of tumor necrosis factor-α and grunulocyte-macrophagc colony-stimulating factor for phagocytosis of Cryptococeus neoformam. Eur. J. Immunol. 22:1447-1454.
12. Cross, C. E., and G. J. Bancroft. 1995. Ingestion of acapsular Cryptococcus neoformans occurs via mannose and β-glucan receptors, resulting in cytokine production and increased phagocytosis of the encapsulated form. Infect. Immun. 63:2604-2611.
13. Currie, B. P. and A. Casadevall. 1994. Estimation of the prevalence of cryptococcal infection among HIV infected individuals in New York City. Clin. Infect. Dis. 19:1029-1033.
14. Dong, Z. M., and J. W. Murphy. 1993. Mobility of human neutrophils in response to Cryptococcus neoformans cells, culture filtrate antigen, and individual components of the antigen. Infect. Immun. 61:5067-5077.
15. Dubois, M. K. A. Gilles, J. K. Hamilton, P. A. Rebers, and F. Smith. 1956. Oilorimetric method for determination of sugars and related substances. Anal. Chem. 28:350-356
16. Eng. R. H. K., E. Bishburg, S. M. Smith, and R. Kaplla. 1986. Cryptococcal infections in patients with acquired immune deficiency syndrome. Am. J. Med. 81:19-23
17. Israel, N., U. Kazan, J. Alcaml, A. Munier, F. Arenzana-Seisdedos, F. Bache- lerie, A. Israel, and J. L. Virelizier. 1989. Tumor necrosis factor stimulates transcription of HIV-1 in human T lymphocytes, independently and syner- gistically with mitogens. J. Immunol. 143:3956-3960.
18. Knight, F. R., D. W. Mackenzie, B. G. Evans, K. Porter, N. J. Barrett, and G. C. White. 1993. Increasing incidence of cryptococcosis in the United Kingdom. J. Infect. 21:185-191.
19. Kozel, T. R., and E. C. Gotschlich. 1982. The capsule of Cryptococcus neofonnam passively inhibits phagocytosis of the yeast by macrophages. J. Immunol. 129:1675-1680.
20. Kozel, T. R., and P. Mastroianni. 1976. Inhibition of phagocytosis by cryptococcal polysaccharide: dissociation of the attachment and ingestion phases of phagocytosis. Infect. Immun. 14:62-67.
21. Kwon-Chung, K. J., and J. E. Bennett. 1984. Epidemiologic differences between two varieties of Cryptococcus neofwmans. Am. J. Epidemiol. 120:123-130.
22. Levitz, S. M., and D. J. DiBenedetto. 1989. Paradoxical role of capsule in murine bronchoalvcolar macrophage-mediated killing of Cryptacoccus neoformons. J. Immunol. 142:659-665
23. Levitz, S. M., and T. P. Farrell. 1990. Growth inhibition of Cryptococcus neoformans by cultured human monocytes: roles of the capsule, opsonins, the culture surface, and cytokincs. Infect. Immun, 58:1201-1209.
24. Levltz, S. M., A. Tabuni, H. Kornfeld, C. C. Reardon, and D. Golenbock. 1994. Production of tumor necrosis factor alpha in human leukocytes stimulated hy Cryptococcus neoformans. Infect. Immun. 62:1975-1981.
25. Levitz, S. M., A. Tabuni, and C. Treseler. 1993. Effect of mannose-binding protein on binding of Cryptococcus neoformans to human phagocytes. Infect. Immun. 61:4891-4893.
26. Macher, A. M,. J. E. Bennett, J. E. Gudek, and M. M. Frank. 1978. Complement depletion in cryptoeoccal sepsis. J. Immunol. 120:1686-1690.
27. Maneuso. G., F. Tomasello, C. von Hunolstein,G. Oreficl, and G. Tetl. 1994. Induction of tumor necrosis factor alpha by the group- and type-specific polysaecharides from type III group B streptococci. Infect. Immun. 62:2748-2753.
28. Matsuyama, T, N. Knbayashi, and N. Yamamoto. 1991. Cytokines and HIV infection: is AIDS a tumor necrosis factor disease? AIDS 5:1405-1417.
29. McGuckin, W. F., and B. F. Mckenzie. 1958. An improved periodic acid fuchsin sulfite staining method for evaluation of glyeoproteins. Clin. Chem. 4:476-483.
30. Murphy, J. W., and G. C. Cozad. 1972. Immunological unresponsiveness induced by cryplococcal capsular polysaccharide assayed by the hemolytic plaque technique. Infect. Immun. 5:896-901.
31. Murphy, J. W., R. L. Mosley, R. Cherniak, G. H. Reyes, T. H. Kozel, and E. Reiss. 1988. Serological, electrophoretic, and biological properties at Cryptococcus neoformnans antigens. Infect. Immun, 56:424-431.
32. Nerad, J. L., J. K. Griffiths, J. W. M. Van der Meer, S. Enures, D. D. Poutslaka, G. T. Keusch, M. Bennish, M. A. Salam, C. A. Dinarello, and J. G. Cannon. 1992. Interlcukin-lβ (IL-lβ). IL-1 receptor antagonist, and TNFα production in whole blood. J. Leukocyte Biol. 52:687-692.
33. Osborne, L, S. Kunkel, and G. J. Nabel. 1989. Tumor necrosis factor alpha and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear faclor kB, Proc. Natl. Acad. Sci. USA 84:2336-2340.
34. Perfect, J. R. 1989. Cryptococcosis. Infect. Dis. Clin. N. Am. 3:77-102.
35. Perfect, J. R., M. M. Hobbs, D. L. Granger, and O. T. Durack. 1988. Cerebrospinal fluid macrophage response to experimental cryptococcal meningitis: relationship between in vivo and in vitro measurements of cytotoxicity. Infect. Immun. 56:849-854.
36. Schelenz, S., R. Malhotra, R. B. Sim, U. Holmskov, and G. J. Bancroft. 1995. Binding of host collectins to the pathogenic yeast Cryptococcus neoformans: human surfactant protein D acts as iin agglutinin for acupsular yeast cells. Infect. Immun. 63:3360-3366.
37. Small, J. M., and T. G. Mitchell. 1986. Binding of purified and radioiodinated capsular polysuccharides from Cryptococcus neoformans serotype A strains to capsule-free mutants. Infect. Immun. 54:742-750.
38. Tetl, G., G. Maneuso, and F. Tomasello. 1993. Cytokine appearance and effects of anti-tumor necrosis factor alpha antibodies in a neonatal rat model of group B streptococal infection. Infect. Immun. 61:227-235.
39. Vartivarian, S. E., C. H. Reyes, E. S. Jacobson, P. G. James, R. Cherniak, V. R. Mumaw, and M. J. Tingler. 1989. Localization of mannoprotein in Cryptococcus neofonmans. J. Bactcrol. 171:6850-6852.
40. Vecchiarelli, A., M. Dottorini, D. Pietrella, C. Monari, C. Retini, T. Todisco, and F. Bistoni. 1994. Role of alveolar macrophages as antigen presenting cells in Cryptococcus neoformans infection. Am. J. Respir. Cell Mol. Biol. 11:1311-137.
41. Vecchiarelli, A., C. Retlni, D. Pietreila, C. Monari, C. Tasclni, T. Beccari, and T. R. Kozel. 1995. Downregulation by cryptococcal polysaccharide of tumor necrosis factor alpha and imerlcukin-1β secretion from human monncyles. Infect. Immun. 63:2919-2923.
42. Zuger, A., E. Louie, R. S. Holzman, M. S. Simberkoff, and J. J. Rahal. 1986. Cryptococcal disease in patients with the acquired immunodeficiency syndrome: diagnostic features and outcome of treatment. Ann. Intern. Med. 104:234-240.